基因组和转录基因组方法推进神经退行性疾病的诊断和预后
1Pathology Department, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Genes
|February 26, 2025
概括
基因组和转录组技术为早期诊断和阿尔茨海默氏症和帕金森氏症等神经退行性疾病的个性化预后提供了新的希望. 这些进展有助于识别基因风险因素和定制治疗的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 基因组学就是基因组学.
背景情况:
- 神经退行性疾病 (阿尔茨海默病,帕金森病,亨廷顿病,ALS) 由于晚期诊断和不可逆转的进展,造成了重大挑战.
- 目前的诊断常常在晚期发现疾病,限制了治疗的有效性.
- 基因组和转录基因组技术正在彻底改变对这些疾病的研究.
研究的目的:
- 探索先进的基因组和转录组技术对神经退行性疾病的早期诊断和个性化预后的影响.
- 突出这些技术如何揭示遗传风险因素,分子途径和生物标志物.
- 讨论将这些发现转化为临床实践和精准医学的可能性.
主要方法:
- 整个基因组测序的测序
- 单细胞RNA测序 (scRNA-seq) 是一种
- 基于CRISPR的屏幕可以使用.
- 全基因组关联研究 (GWAS)
- 多基因风险分数 (PRS) 是指多基因风险分数.
- 空间转录组学 空间转录组学
- 功能性基因组学是一种功能性基因组学.
主要成果:
- 基因组方法确定了特定疾病的遗传风险因素和分子途径.
- 转录组研究揭示了与疾病进展相关的特定阶段生物标志物.
- GWAS,PRS和空间转录学使患者根据风险和预后进行分层.
- 功能基因组学揭示了可操作的目标 (例如,ALS中的ATXN2,AD中的TREM2).
结论:
- 基因组和转录基因组技术为理解和潜在地干预神经退行性疾病提供了强大的工具.
- 这些进步促进了早期诊断,个性化预后和向治疗的开发.
- 尽管由于疾病的复杂性,临床翻译存在挑战,但未来的基因技术整合有望改善患者的治疗结果和精确医学.
相关概念视频
Genomics
35.6K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
35.6K
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422


